Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation.
We report a case of early-onset acute Guillain-Barre syndrome associated with reactivation of Epstein-Barr virus (EBV) infection after nonmyeloablative stem cell transplantation (NST). Reactivation of EBV infection preceded disease onset, and the virus load increased concomitantly with disease progression (doubling time, 2.7 days). This case raises concern about the expanding scope of manifestations associated with reactivation of EBV infection after NST.
Department of Bone Marrow Transplantation and Cancer Chemotherapy, Hadassah University Hospital, Jerusalem, Israel. mbitan@hadassah.org.il
Menachem
M
Bitan
Reuven
R
Or
Michael Y
MY
Shapira
Nurith
N
Mador
Igor B
IB
Resnick
Niveen
N
Saleh
Klaus M
KM
Weinberger
Simcha
S
Samuel
Esther
E
Schechter
Shimon
S
Slavin
Dana G
DG
Wolf
D000961:Antilymphocyte Serum / Q000009:adverse effects; D002066:Busulfan / Q000009:adverse effects; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000821:virology; D020275:Guillain-Barre Syndrome / Q000209:etiology* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012493:Samarium / Q000009:adverse effects; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives; D014775:Virus Activation / Q000187:drug effects*
D000961:Antilymphocyte Serum; D012493:Samarium; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine